However, the overexpression of either SP1 or LOXL2 did not significantly correlate with poor clinical outcomes including lymph node metastasis, depth of invasion, or lymphovascular invasion. The gene discussed is SP1; the disease is metastatic malignant neoplasm in the lymph nodes.